Altogether, these analyses confirm that the gRNAs employed in PPCs were efficacious and specific, as no undesired effects were observed, making them attractive to be employed as a therapeutic approach for STGD1 cases caused by pathogenic variants of intron 30 of the ABCA4 gene. This evidence concerns the gene ABCA4 and severe early-childhood-onset retinal dystrophy.